The group has three geographic segments, being Australia, Asia Pacifi c, and Europe, Middle East and Africa (‘EMEA’) and one business segment being the research and development and marketing of diagnostic products for infectious diseases.
 |
 |
 |
- Shareholder Letter
- Chairman’s Message
- Board of Directors
- Managing Directors’ Review of Operations
- Executive Team
- Patent / Trademark Status
- Directors' Report
- Corpoate Governance Report
- Auditor’s Independant Declaration
- Independent Audit report
- Directors’ Declaration
- Statement of Financial Performance
- Statement of Cash Flows
- Statement of Changes in Equity
- Notes to the Financial Statements
- » Summary of accounting policies
- » Loss from operations
- » IncomeTaxes
- » Key management personal remuneration
- » Share based payment arrangements
- » Remuneration of auditors
- » Current trade and other receivables
- » Inventories
- » Non current trade and other receivables
- » Property, plant and equipment
- » Non current financial assets
- » Other intangible assets
- » Trade and other payables
- » Current borrowings
- » Current provisions
- » Issued capital
- » Reserves
- » Accumulated losses
- » Loss per share
- » Expenditure commitments
- » Contingencies
- » Subsidiaries
- » Segment information
- » Related party disclosures
- » Subsequent events
- » Notes to the cash flow statement
- » Financial instruments
- » Impacts of the adoption of Australian equivalents to International Financial Reporting Standards
- » Additional company information
- Additional ASX Information
Segment information
